China’s National Medical Products Administration (NMPA) has approved JASCAYD® (nerandomilast), marking the first new treatment for adults with progressive pulmonary fibrosis (PPF) in more than five years. The decision represents a major breakthrough for …

Ingelheim: Boehringer Ingelheim has announced that China' … Head of Human Pharma at Boehringer Ingelheim. “While this initial approval in … the findings indicate that the drug effectively slows the decline of …

… on brand-driven marketing, innovative drug delivery formats, and robust self … the over the counter (OTC) drugs market, provides pain relief, allergy … Pharmaceutical Group, Procter & Gamble, Boehringer Ingelheim International GmbH, Johnson & Johnson …

… HIV drug market. Which Companies Are Currently Leading In The HIV Drugs … ; Johnson • Merck & Co. Inc. • Boehringer Ingelheim International GmbH • Cipla • Aurobindo Pharma … ;hiv-drug-global-market-report Which Regions Are Dominating The HIV Drugs …

… agonists. These are injectable drugs that mimic natural gut … have revolutionized the obesity drug race with its semaglutide … including its next-generation drug candidate CargiSema.  The weight … - MariTide (Phase 3) Boehringer Ingelheim - Survodutide (Phase 3) …

… to generate new evidence about drug efficacy and safety. It is … for Alexion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dimerix, Eli Lilly, Novartis, Novo … research support from AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and travel support …

… on placebo and people on drug,” Taub said. “A … then giving them a drug where they’re going … consulting for Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Jazz, Medtronic … steering committee member for Arrowhead, Boehringer Ingelheim, Cleerly Health, Medtronic, …

… in the past, with both drugs conferring at least 5% weight … reports advising for Altimmune, Atria, Boehringer Ingelheim, CinFina Pharma, Corteria, Eli Lilly …

… peptide pipeline into orally delivered drug modalities. The partnership signals … industry interest in diversifying obesity drug modalities amid rising efficacy … dual agonist in partnership with Boehringer Ingelheim. Zealand recently paused development of …

… two of their cancer drugs as they eye … drugs for infants. The FDA approved Augmentin XR, the first drug … AI-powered drug platform that discovers new drug candidates discovered … untreatable mosquito-borne disease. Boehringer Ingelheim unveiled more details about …